Glaucoma Market Share, Size, Trends, Industry Analysis Report, By Drug Class; By Distribution Channel (Hospital pharmacy, Retail pharmacy, and Online pharmacy); By Disease Type; By Region; Segment Forecast, 2023 - 2032

Glaucoma Market Share, Size, Trends, Industry Analysis Report, By Drug Class; By Distribution Channel (Hospital pharmacy, Retail pharmacy, and Online pharmacy); By Disease Type; By Region; Segment Forecast, 2023 - 2032

The global glaucoma market size is expected to reach USD 9,154.4 million by 2032, according to a new study by Polaris Market Research. The report “Glaucoma Market Share, Size, Trends, Industry Analysis Report, By Drug Class; By Distribution Channel (Hospital pharmacy, Retail pharmacy, and Online pharmacy); By Disease Type; By Region; Segment Forecast, 2023 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Glaucoma, a prevalent ocular condition, is expected to affect many individuals worldwide. The World Glaucoma Association predicts the disease will impact 79.6 million people in 2020 and rise to 111.8 million by 2040. In the United States alone, glaucoma affects 3 million people, with 2.7 million of them being over 40. The increasing incidence rates and advancements in therapeutic strategies are driving the expansion of the glaucoma market.

Technological improvements in the ophthalmology sector play a significant role in the positive outlook for the glaucoma market. The demand for cutting-edge surgical techniques, such as micro-invasive glaucoma surgery (MIGS) and selective laser trabeculoplasty (SLT), is driving industry growth. Moreover, advancements in medical imaging, optical coherence tomography (OCT), and progression analysis software are increasing the popularity of optometrists. Incorporating laser therapies as first-line treatments and developing new medications for glaucoma also contribute to the market's expansion.

The COVID-19 pandemic had adverse effects on the sales of glaucoma treatments. Preventive lockdown measures and diverted healthcare resources limited access to care for glaucoma patients. Many ophthalmology clinics were repurposed as COVID-19 wards, which hindered patient follow-ups. Furthermore, the fear of contracting the virus deterred older individuals from visiting clinical settings, decreasing market demand. However, telemedicine platforms emerged as a viable solution during the pandemic, enabling patients to access prompt care and contributing to the overall expansion of the industry.

Glaucoma Market Report Highlights

The prostaglandin analogs segment held the largest share of the glaucoma market. Their widespread use, effectiveness with once-daily dosing, and benefits in combination therapy contribute to the segment's projected growth and market dominance.

The open-angle disease type is the dominant segment in the glaucoma market due to its high prevalence and available therapeutic medications specifically designed for its treatment.

North America is dominant in the glaucoma market due to its well-developed hospital infrastructure, effective treatment framework, and increasing FDA approvals and drug launches.

The global key market players include Allergan PLC, Aristo Pharmaceuticals Pvt. Ltd., Aerie Pharmaceuticals Company, Akorn operating company LLC, Bausch & Lomb Incorporated, Cipla Incorporation, Fera Pharmaceuticals, LLC, Inotek Pharmaceuticals, Merck KGaA, Novartis AG, Pfizer Incorporation, Santen Pharmaceutical Co., Ltd., Teva Pharmaceutical Industries Ltd., and Valeant Pharmaceuticals International, Inc.

Polaris Market Research has segmented the Glaucoma market report based on drug class, distribution channel, disease type, and region:

Glaucoma, Drug Class Outlook (Revenue - USD Million, 2019 - 2032)

Prostaglandin Analogs

Beta-blockers

Adrenergic Agonists

Carbonic Anhydrase Inhibitors

Others

Glaucoma, Distribution Channel Outlook (Revenue - USD Million, 2019 - 2032)

Hospital pharmacy

Retail pharmacy

Online Pharmacy

Glaucoma, Disease Type Outlook (Revenue - USD Million, 2019 - 2032)

Open-angle

Angle-closure

Others

Glaucoma, Regional Outlook (Revenue - USD Million, 2019 - 2032)

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa